[{"address1": "Northern Design Centre", "address2": "Baltic Business Quarter", "city": "Gateshead", "zip": "NE8 3DF", "country": "United Kingdom", "phone": "44 1915 118 500", "website": "https://www.shieldtherapeutics.com", "industry": "Drug Manufacturers - Specialty & Generic", "industryKey": "drug-manufacturers-specialty-generic", "industryDisp": "Drug Manufacturers - Specialty & Generic", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Shield Therapeutics plc, a commercial stage specialty pharmaceutical company, focuses on commercialization of pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was incorporated in 2008 and is based in Gateshead, the United Kingdom.", "fullTimeEmployees": 73, "companyOfficers": [{"maxAge": 1, "name": "Mr. Anders  Lundstrom", "age": 61, "title": "Interim CEO & Independent Non-Executive Director", "yearBorn": 1962, "fiscalYear": 2023, "totalPay": 54035, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Christian  Schweiger M.D., Ph.D.", "age": 57, "title": "Co-Founder & Non Executive Director", "yearBorn": 1966, "fiscalYear": 2023, "totalPay": 47602, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Santosh  Shanbhag", "age": 45, "title": "Chief Financial Officer", "yearBorn": 1978, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Lucy Kate Huntington-Bailey", "title": "General Counsel & Company Secretary", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Suzanne  Wood", "title": "Group HR Director", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Carol  Akinola", "title": "Head of Pharmacovigilance & Medical Information", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Andrew  Hurley", "age": 54, "title": "Chief Commercial Officer", "yearBorn": 1969, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Kate  Armanetti", "title": "Senior Director of People & Culture", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "open": 0.018, "dayLow": 0.018, "dayHigh": 0.018, "regularMarketOpen": 0.018, "regularMarketDayLow": 0.018, "regularMarketDayHigh": 0.018, "beta": 1.27, "volume": 1000000, "regularMarketVolume": 1000000, "averageVolume": 158, "bid": 0.045, "ask": 0.056, "marketCap": 39942540, "fiftyTwoWeekLow": 0.0135, "fiftyTwoWeekHigh": 0.151, "priceToSalesTrailing12Months": 3.052544, "fiftyDayAverage": 0.022, "twoHundredDayAverage": 0.04437725, "trailingAnnualDividendYield": "NaN", "currency": "USD", "enterpriseValue": 23502240, "profitMargins": -2.5443602, "floatShares": 410133821, "sharesOutstanding": 782056000, "heldPercentInsiders": 0.62406, "heldPercentInstitutions": 0.11883, "impliedSharesOutstanding": 1815570048, "bookValue": 0.019, "priceToBook": 1.1578947, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -33293000, "trailingEps": -0.05, "enterpriseToRevenue": 1.796, "enterpriseToEbitda": -0.756, "52WeekChange": -0.84827584, "SandP52WeekChange": 0.24822903, "exchange": "OQB", "quoteType": "EQUITY", "symbol": "SHIEF", "underlyingSymbol": "SHIEF", "shortName": "SHIELD THERAPEUTICS PLC", "longName": "Shield Therapeutics plc", "firstTradeDateEpochUtc": 1575642600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "9b548f93-7e13-35e7-8bb0-bdbf5c912123", "messageBoardId": "finmb_115221091", "gmtOffSetMilliseconds": -14400000, "currentPrice": 0.022, "recommendationKey": "none", "totalCash": 13948000, "totalCashPerShare": 0.018, "ebitda": -31078000, "totalDebt": 20245000, "quickRatio": 1.832, "currentRatio": 2.276, "totalRevenue": 13085000, "debtToEquity": 134.67, "revenuePerShare": 0.018, "returnOnAssets": -0.5193, "returnOnEquity": -3.08597, "freeCashflow": -28964876, "operatingCashflow": -37126000, "revenueGrowth": 2.033, "grossMargins": 0.30776, "ebitdaMargins": -2.3750901, "operatingMargins": -2.26146, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-08-15"}]